Zag Bio

📍 Cambridge, United States🗓 Founded 2022👥 26 employees💰 Last funded Jun 2025
Biotechnology Research🌐 zagbio.com
Website LinkedIn
Zag Bio is a group of bold scientists and expert drug developers, formed to pioneer thymus-targeted medicines to treat and prevent autoimmune diseases. We have discovered a novel therapeutic approach to restore central immune tolerance by creating bifunctional antibodies that deliver self-antigens to specialized antigen-presenting cells in the thymus. This enables us to harness the body’s natural process for training immune cells to recognize and tolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes its lead program ZAG-101, a bifunctional antibody that delivers pancreatic beta cell antigens to the thymus to treat Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases. Zag Bio is located in Cambridge, MA, and is supported by a broad syndicate of life sciences investors. Zag Bio’s team is built on the mission of improving the lives of patients by charting a new direction for better therapies for autoimmune diseases, based on unique insights and understanding of the biology of the thymus.
3
Total investors
2
Early stage
1
Mid stage
0
Late stage
2022
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2023–2025 · investors recorded per year
2023220251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Zag Bio?
Zag Bio has 3 investors on record on gritt.io, including 2 early-stage backers, 1 mid-stage.
When did Zag Bio last raise funding?
The most recent investment in Zag Bio recorded on gritt.io was in June 2025.
When was Zag Bio founded?
Zag Bio was founded in 2022.
What industry is Zag Bio in?
Zag Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Zag Bio based?
Zag Bio is headquartered in Cambridge, United States.